Effect of Self-administered tDCS in Patients With MDD

• Status: Completed
• Trial end date: 2019-05-02
• Target enrollment: 0
• Participant gender: All

Summary

In this randomized, single-blinded clinical trial, 58 patients with major depressive disorder were assigned to active and sham tDCS stimulation groups in a 1:1 ratio, and treatment responses were evaluated biweekly over six weeks.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Jeong-Ho Chae
• Collaborator: Ybrain Inc.
• Treatments: Antidepressive Agents; Citalopram

Criteria

Inclusion Criteria:

• Has a diagnosis of a major depressive disorder as confirmed by the SCID-IV and MINI (without psychotic features)

• Greater than 22 points of Montgomery-Asberg Depression Rating Scale

• Aged 19 to 65.

• Has provided informed consent

• Has received Escitalopram as a combined antidepressant during the study period

Exclusion Criteria:

• Has other mental disorders diagnosed by Axis-I, except major depressive disorder (However, subject who is diagnosed as both major depressive disorder as well as anxiety disorder can participate the study.)

• History of suicidal attempt in the last 6 months

• Diagnosed with bipolar or psychotic major depressive disorder

• Diagnosed with other depressive disorders: dysthymic disorder, and depressive disorders that are not elsewhere classified.

• Has hypersensitivity to Escitalopram ingredients

• A score of 5 or greater for the question #10 in MADRS

• Diagnosed with closed angle glaucoma or has a history of glaucoma.

• History of participation in other clinical trials within 30days.

• A major and/or unstable medical or neurologic illness

• Currently taking substances pimozide

• Pregnant or has a positive pregnancy serum test.